When considering study drug discontinuation or use of rescue medication (trial product estimand results), the weight loss resulting from the use of oral semaglutide was up to 5 kg, while that associated with other active comparators ranged from 0.8 to 3.8 kg, and that associated with placebo ranged from 0.1 to + 0.6 kg [35,36,37,38,39,40]
June 13-16, 2026
Clinical trials show LDL cholesterol reductions of 17% and triglyceride reductions of 515%, significantly less than statins
At the top dose, 45.3% of participants lost at least 30% of their body weight, and 65.3% reached a BMI below 30
Los resultados anunciados corresponden al estudio HRS9531-302 , un ensayo clnico multicntrico, aleatorizado, doble ciego y controlado con placebo de fase III ( NCT06650007 ), diseado para evaluar la eficacia, la seguridad y la tolerabilidad de Ribupatide en adultos con diabetes tipo 2 cuyo control glucmico segua siendo insuficiente tras las intervenciones basadas en dieta y ejercicio